Abstract
TNF-naive and -failure subgroups. Adverse events were comparable across treatment groups; serious adverse events were more common in the eldelumab 10 and 20 mg/kg groups (7.5% and 9.8%, respectively) compared with placebo (5.0%), driven by infusion-related events. Rates of infection were similar across all groups. Conclusion: Induction treatment with eldelumab 10 or 20 mg/kg IV demonstrated trends towards efficacy as assessed by both clinical and endoscopic endpoints. Safety signals were consistent with those reported previously for eldelumab.1,2 1. Sandborn WJ, et al. Gastroenterology 2014;146(Suppl 1):S-55. 2. Mayer L, et al. Gut 2014;63:442-50. Clinical efficacy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
